Joanna Collicutt McGrath

Joanna Collicutt McGrath

Auto-generated profile, based on publicly available information

Joanna Collicutt McGrath

School of Life Sciences, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2015 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JMJohn C McGrath
John C McGrath
ELElliot Lilley
Elliot Lilley

1 February 1982 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JMJ.C. McGrath
J.C. McGrath

1 May 1991 in Hypertension
Verified
Journal Article
Closed access
PDF file
SGS A Griffin
S A Griffin
WBW C Brown
W C Brown
FMF MacPherson
F MacPherson
JMJ C McGrath
J C McGrath
VWV G Wilson
V G Wilson
ALA F Lever
A F Lever
Angiotensin II, when given in low doses, raises blood pressure slowly. When tested in vitro on vascular smooth muscle cells, it has mitogenic and trophic effects; it is not known if it has these effects in vivo. Our purpose was to determine whether vascular hypertrophy develops during slow pressor infusion of angiotensin II and, if so, whether it is pressure induced. Three experiments were done in rats infused subcutaneously with angiotensin II (200 ng/kg/min) by minipump for 10-12 days. Experiment 1: Angiotensin II gradually raised systolic blood pressure (measured in the tail) from 143 +/- 2 to 208 +/- 8 mm Hg (mean +/- SEM), significantly suppressing plasma renin and increasing threefold (NS) plasma angiotensin II. There was no loss of peptide in the pump infusate when tested at the end of the experiment. Experiment 2: In the perfused mesenteric circulation, vasoconstrictor responses to norepinephrine, vasopressin, and KCl were enhanced in rats given a slow pressor infusion of angiotensin II, but sensitivity of responses was not altered. This combination of changes suggests that vascular hypertrophy develops during slow pressor infusion of angiotensin II. Experiment 3: Vessel myography was done after angiotensin II infusion with and without a pressor response. Angiotensin II raised systolic blood pressure, increased heart weight, and produced myographic changes of vascular hypertrophy in the mesenteric circulation, increasing media width, media cross-sectional area, and media/lumen ratio. Hydralazine given with angiotensin II prevented the rise of pressure and the cardiac effect but not the vascular changes. Two-way analysis of variance showed that angiotensin II significantly increased media width, media cross-sectional area, and media/lumen ratio, all independent of hydralazine. Thus, although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism.


1 October 2003 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
ABAna M. Briones
Ana M. Briones
Jose M Gonzalez-GranadoJose M Gonzalez-Granado
Jose M Gonzalez-Granado
BSBeatriz Somoza
Beatriz Somoza
Jesús GiraldoJesús Giraldo
Jesús Giraldo
CDCraig J. Daly
Craig J. Daly
Silvia ArribasSilvia Arribas
Silvia Arribas
Chronic hypertension is associated with resistance artery remodelling and mechanical alterations. However, the contribution of elastin has not been thoroughly studied. Our objective was to evaluate the role of elastin in vascular remodelling of mesenteric resistance arteries (MRA) from spontaneously hypertensive rats (SHR). MRA segments from Wistar Kyoto rats (WKY) and SHR were pressurised under passive conditions at a range of physiological pressures with pressure myography. Confocal microscopy was used to determine differences in the quantity and organisation of elastin in intact pressure‐fixed arteries. To assess the contribution of elastin to MRA structure and mechanics, myograph‐mounted vessels were studied before and after elastase incubation. When compared with WKY, MRA from SHR showed: (1) a smaller lumen, (2) decreased distensibility at low pressures, (3) a leftward shift of the stress‐strain relationship, (4) redistribution of elastin within the internal elastic lamina (IEL) leading to smaller fenestrae but no change in fenestrae number or elastin amount. Elastase incubation (1) fragmented the structure of IEL in a concentration‐dependent fashion, (2) abolished all the structural and mechanical differences between strains, and (3) decreased distensibility at low pressures. The study shows the overriding role of elastin in determining vascular dimensions and mechanical properties in a resistance artery. In addition, it informs hypertensive remodelling. MRA remodelling and increased stiffness are accompanied by elastin restructuring within the IEL and elastin degradation reverses structural and mechanical alterations of SHR MRA. Differences in elastin organisation are, therefore, a central element in small artery remodelling in hypertension.

1 November 2003 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CDCraig J Daly
Craig J Daly
JMJohn C McGrath
John C McGrath